Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study
Aim: Non-alcoholic steatohepatitis (NASH), ormetabolic dysfunction-associated steatohepatitis (MASH), is a severe form of non-alcoholic fatty liver disease (NAFLD) ormetabolic dysfunction-associated liver disease (MASLD), that may progress to advanced liver disease. Costs associated with progressi...
Saved in:
| Main Authors: | Yestle Kim, Joseph Medicis, Matthew Davis, Dominic Nunag, Robert Gish |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2024-11-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01) -
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01) -
Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01) -
Non-Targeted Metabolomics Reveal Apomorphine’s Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis
by: Hideo Ogiso, et al.
Published: (2024-10-01) -
A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
by: Abdul Haseeb Hasan, et al.
Published: (2025-01-01)